GR1001161B - Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη. - Google Patents

Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη.

Info

Publication number
GR1001161B
GR1001161B GR900100648A GR900100648A GR1001161B GR 1001161 B GR1001161 B GR 1001161B GR 900100648 A GR900100648 A GR 900100648A GR 900100648 A GR900100648 A GR 900100648A GR 1001161 B GR1001161 B GR 1001161B
Authority
GR
Greece
Prior art keywords
present
receptor
adhesion
lymphocytes
inhibiting
Prior art date
Application number
GR900100648A
Other languages
English (en)
Other versions
GR900100648A (en
Inventor
Elisabeth Wayner
Original Assignee
Hutchinson Cancer Research Cen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23591680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR1001161(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchinson Cancer Research Cen filed Critical Hutchinson Cancer Research Cen
Publication of GR900100648A publication Critical patent/GR900100648A/el
Publication of GR1001161B publication Critical patent/GR1001161B/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/7055Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

H παρούσα εφεύρεση αναφέρεται σε μια μέθοδο για την αναστολή της προσκόλλησης του ενός κυττάρου σε ένα άλλο που περιλαμβάνει την παρεμβολή στην αλληλεπίδραση μεταξύ του υποδοχέα εξωκυτταρικής μήτρας και του προσδέτη του. Η εφεύρεση βασίζεται στην ανακάλυψη ότι ο α4β1 υποδοχέας εξωκυτταρικής μήτρας προάγει την προσκόλληση των λεμφοκυττάρων σε ενδοθηλιακά κύτταρα μέσω της σύνδεσης σε μια καθορισμένη πεπτιδική αλληλουχία. Πριν από την παρούσα εφέρευση, δεν είχε ταυτοποιηθεί ο προσδέτης του α4β1 υποδοχέα, ούτε ήταν γνωστή η λειτουργία του α4β1 υποδοχέα επί της λεμφοκυτταρικής προσκόλλησης. Παρεμποδίζοντας την αλληλεπίδραση μεταξύ α4β1 υποδοχέα και των προσδετών του με την χρησιμοποίηση αντισωμάτων ή καθορισμένων πεπτιδικών αλληλουχιών, η παρούσα εφεύρεση επιτρέπει, για πρώτη φορά, την ειδική παρεμβολή στην μετακίνηση των λεμφοκυττάρων μέσα από το αγγειακό ενδοθήλιο και προς τους ιστούς. Η παρούσα εφεύρεση, επομένως, έχει ιδιαίτερη κλινική χρησιμότητα στην καταστολή των ανόσων αποκρίσεων; σε διάφορες ειδικές ενσωματώσεις της εφεύρεσης, η προσκόλληση των λεμφοκυττάρων στο ενδοθήλιο μπορεί να ανασταλλεί συστηματικά, ή μπορεί, εναλλακτικά, να εντοπισθεί σε ειδικούς ιστούς ή περιγεγραμμένες επιφάνειες. Κατά συνέπεια, η παρούσα εφεύρεση προβλέπει για την θεραπεία ασθενειών που περιλαμβάνουν αυτοάνοσες αποκρίσεις όπως άλλων χρόνιων ή υποτροπιαζουσών ενεργοποιήσεων του άνοσου συστήματος, περιλαμβάνοντας αλλεργία, άσθμα, και χρόνιες φλεγμονώδεις καταστάσεις του δέρματος. ω
GR900100648A 1989-09-01 1990-08-28 Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη. GR1001161B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40238989A 1989-09-01 1989-09-01

Publications (2)

Publication Number Publication Date
GR900100648A GR900100648A (en) 1992-01-20
GR1001161B true GR1001161B (el) 1993-05-24

Family

ID=23591680

Family Applications (2)

Application Number Title Priority Date Filing Date
GR900100648A GR1001161B (el) 1989-09-01 1990-08-28 Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη.
GR930100041A GR1001372B (el) 1989-09-01 1990-08-28 Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GR930100041A GR1001372B (el) 1989-09-01 1990-08-28 Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη.

Country Status (19)

Country Link
EP (2) EP0489837B2 (el)
JP (1) JP3357359B2 (el)
KR (1) KR100188459B1 (el)
AT (1) ATE253642T1 (el)
AU (1) AU654657B2 (el)
CA (1) CA2065292C (el)
DD (1) DD297562A5 (el)
DE (3) DE122006000044I2 (el)
DK (1) DK0489837T4 (el)
ES (1) ES2210225T5 (el)
FI (2) FI116793B (el)
GR (2) GR1001161B (el)
IE (2) IE20040028A1 (el)
IL (3) IL113261A (el)
LU (1) LU91273I2 (el)
NL (1) NL300240I2 (el)
NZ (1) NZ235131A (el)
PT (1) PT95180A (el)
WO (1) WO1991003252A1 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
AU3420693A (en) * 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DK0626861T4 (da) * 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
IL102646A (en) * 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
DK0670735T3 (da) 1992-11-13 1997-07-28 Univ Washington Perifisering af hæmotopoietiske stamceller.
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
EP0689609B2 (en) 1993-03-18 2005-04-13 N.V. Innogenetics S.A. Process for typing hla-b using specific primers and probes sets
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
FR2724393A1 (fr) * 1994-09-12 1996-03-15 Inst Nat Sante Rech Med Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
WO1997035557A1 (en) * 1996-03-22 1997-10-02 Kao Corporation External skin-care composition
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
US7125650B2 (en) 2004-07-20 2006-10-24 Roberts David H Method for bump exposing relief image printing plates
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
IT202400002376A1 (it) * 2024-02-05 2025-08-05 Univ Degli Studi Di Brescia Marcatori plasmatici di sindrome di ehlers-danlos ipermobile, disordini nello spettro dell’ipermobilità articolare, osteoartrite, artrite reumatoide e artrite psoriasica

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells

Also Published As

Publication number Publication date
KR100188459B1 (ko) 1999-06-01
PT95180A (pt) 1991-05-22
FI920899A0 (fi) 1992-02-28
DD297562A5 (de) 1992-01-16
GR900100648A (en) 1992-01-20
FI20050941L (fi) 2005-09-21
DE69034116T3 (de) 2014-06-18
DE69034116D1 (de) 2003-12-11
WO1991003252A1 (en) 1991-03-21
FI116793B (fi) 2006-02-28
IE20040028A1 (en) 2004-05-05
KR920703086A (ko) 1992-12-17
ATE253642T1 (de) 2003-11-15
EP1366769A1 (en) 2003-12-03
NZ235131A (en) 1993-03-26
DE122006000044I2 (de) 2011-01-13
NL300240I2 (nl) 2007-03-01
DE122006000044I1 (de) 2007-04-19
CA2065292A1 (en) 1991-03-02
GR1001372B (el) 1993-10-29
JPH05503070A (ja) 1993-05-27
IE903169A1 (en) 1991-03-13
IL95501A (en) 1997-04-15
ES2210225T5 (es) 2014-02-04
DE69034116T2 (de) 2004-08-26
DK0489837T4 (da) 2013-11-18
CA2065292C (en) 2001-05-29
ES2210225T3 (es) 2004-07-01
IL113261A0 (en) 1995-07-31
EP0489837A4 (en) 1993-06-16
JP3357359B2 (ja) 2002-12-16
AU6354290A (en) 1991-04-08
FI118842B (fi) 2008-04-15
EP0489837B1 (en) 2003-11-05
IL113261A (en) 1996-10-16
EP0489837A1 (en) 1992-06-17
EP0489837B2 (en) 2013-11-13
AU654657B2 (en) 1994-11-17
LU91273I2 (fr) 2006-10-10
DK0489837T3 (da) 2004-03-01
NL300240I1 (nl) 2006-10-02

Similar Documents

Publication Publication Date Title
GR1001161B (el) Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη.
DE3586619D1 (de) Haematologische zusammensetzungen als referenz fuer drei populationen von leukocyten, verfahren zu deren herstellung und deren verwendung in ganzbluttestverfahren.
ATE127925T1 (de) Verfahren zur bestimmung von antiphospholipid antikörpern.
DE69420556D1 (de) Assay für troponin i aus dem herzmuskel
ATE78097T1 (de) Verfahren zur bestimmung von mimitopen.
DE69019795D1 (de) Verfahren zur Feststellung der Empfindlichkeit von HIV-1 für Zidovudine und dazu geeignete Oligonukleotide.
DK21985A (da) Monoklonale antistoffer mod ikke-smaacellet lungecancer
DE59109048D1 (de) Inhibitoren zur antikoagulierenden Vorbehandung von Blutproben
ATE306932T1 (de) Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
DE59408917D1 (de) Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
Gurewich et al. Pathogenesis of venous thrombosis in relation to its prevention by dextran and heparin
Kaneider et al. Heparan sulfate proteoglycans are involved in opiate receptor-mediated cell migration
FI883351A0 (fi) Diagnostisk metod foer paovisande av stoerningar i rna-as l.
ATE205600T1 (de) Leukozytadhaesiontest
Lebedev et al. Serum levels of different forms of soluble CD38 antigen in burned patients
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
NO168311C (no) Monoklonale antistoffer for humane ikke-smaacelle lungekarsinomer, cellelinjer som produserer disse samt diagnostisksett
Savage et al. Inhibition of TCR‐mediated shedding of L‐selectin (CD62L) on human and mouse CD4+ T cells by metalloproteinase inhibition: analysis of the regulation of Th1/Th2 function
Kerber PREHISTORIC HUMAN OCCUPATION AND CHANGING ENVIRONMENT OF POTOWOMUT NECK, WARWICK, RHODE ISLAND: AN INTERDISCIPLINARY APPROACH (SETTLEMENT)
O'Brien Neuronal adhesion molecules signal through FGF receptor
BR8106454A (pt) Suporte para saco de drenagem de liquidos corporais bem como aparelho para o recebimento e coleta de urina ou outro liquido corporal
NO963910L (no) Fremgangsmåte for bestemmelse av en suppressorkomponent av human immunstatus og en måte for gjennomföring
OHTAKA EFFECT OF ACUPUNCTURE UPON PAIN IN HANSEN'S DISEASE
Davisson Invisible owners of painted ladies and other homes: Women property owners in Nevada City, California, 1856-1876.
Roper LAW ENFORCEMENT SELECTION REQUIREMENTS: A NATIONAL ANALYSIS.

Legal Events

Date Code Title Description
MA Right expired